Loading…
Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis
The aim of this study was to investigate the status of serum lipids during endocrine therapy. We retrospectively analysed lipid profiles during the 5-year treatment of 1487 consecutive postoperative BC patients. Lipid parameters included triglycerides (TG), total cholesterol (TC), low-density lipopr...
Saved in:
| Published in: | Frontiers in oncology 2022-01, Vol.11, p.670897-670897 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c462t-ca926ed18d416d45cd6410f06b5e0dae6488ded46e92c0a4bed70e48f345332d3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c462t-ca926ed18d416d45cd6410f06b5e0dae6488ded46e92c0a4bed70e48f345332d3 |
| container_end_page | 670897 |
| container_issue | |
| container_start_page | 670897 |
| container_title | Frontiers in oncology |
| container_volume | 11 |
| creator | He, Tao Li, Xu Li, Jiayuan Wang, Zhu Fan, Yuan Li, Xiusong Fu, Zhoukai Wu, Yunhao Lv, Qing Luo, Ting Zhong, Xiaorong Chen, Jie |
| description | The aim of this study was to investigate the status of serum lipids during endocrine therapy.
We retrospectively analysed lipid profiles during the 5-year treatment of 1487 consecutive postoperative BC patients. Lipid parameters included triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C). Those biomarkers were measured at baseline and 1, 2, 3, 4 and 5 years following the initiation of endocrine therapy.
For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifen (TAM) group compared with baseline levels ( |
| doi_str_mv | 10.3389/fonc.2021.670897 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_96471066cd5442e6a6ebec8e81740a80</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_96471066cd5442e6a6ebec8e81740a80</doaj_id><sourcerecordid>2625265948</sourcerecordid><originalsourceid>FETCH-LOGICAL-c462t-ca926ed18d416d45cd6410f06b5e0dae6488ded46e92c0a4bed70e48f345332d3</originalsourceid><addsrcrecordid>eNpVks9rFDEUxwdRbKm9e5IcvcyaX5PJeBDqWrWwoEhFPYW3yZvdlNlkTGYKi_-8WbeWNpd8efm-T8LLt6peMroQQndv-hjsglPOFqqlumufVKecC1l3Uvx8-kCfVOc539CyVEMZFc-rE9EwxpTip9WflR-9I8sthA1m8mFOPmzIZXDRFoXkeosJxj3xgbxPCHkiSwgWE_kKk8cw5bcHC_mGeR6mTGJPgDT1L4RUajDUP2IaXJFTinlEO_lbJBcBhn32-UX1rIch4_ndflZ9_3h5vfxcr758ulperGorFZ9qCx1X6Jh2kiknG-uUZLSnat0gdYBKau3QSYUdtxTkGl1LUepeyEYI7sRZdXXkugg3Zkx-B2lvInjzrxDTxkCavB3QdEq2jCplXSMlRwUK12g1atZKCpoW1rsja5zXO3S2jCDB8Aj6-CT4rdnEW6M1ZYqJAnh9B0jx94x5MjufLQ4DBIxzNlzxhqumk7pY6dFqy_Bywv7-GkbNIQLmEAFziIA5RqC0vHr4vPuG_x8u_gJuea5F</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2625265948</pqid></control><display><type>article</type><title>Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis</title><source>PubMed Central</source><creator>He, Tao ; Li, Xu ; Li, Jiayuan ; Wang, Zhu ; Fan, Yuan ; Li, Xiusong ; Fu, Zhoukai ; Wu, Yunhao ; Lv, Qing ; Luo, Ting ; Zhong, Xiaorong ; Chen, Jie</creator><creatorcontrib>He, Tao ; Li, Xu ; Li, Jiayuan ; Wang, Zhu ; Fan, Yuan ; Li, Xiusong ; Fu, Zhoukai ; Wu, Yunhao ; Lv, Qing ; Luo, Ting ; Zhong, Xiaorong ; Chen, Jie</creatorcontrib><description>The aim of this study was to investigate the status of serum lipids during endocrine therapy.
We retrospectively analysed lipid profiles during the 5-year treatment of 1487 consecutive postoperative BC patients. Lipid parameters included triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C). Those biomarkers were measured at baseline and 1, 2, 3, 4 and 5 years following the initiation of endocrine therapy.
For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifen (TAM) group compared with baseline levels (
<0.05), and this decline remained for the following 4 years. Additionally, LDL levels were significantly lower in the TAM group than in the nonendocrine group at all assessment time points (
<0.05). Similarly, TC levels also decreased in the TAM group compared with baseline levels at all assessment time points (
<0.05), and compared with the levels in the nonendocrine group, TC levels were also lower for the first 4 years. For postmenopausal BC patients, there was no significant difference in the lipid profiles (TG, TC, LDL and HDL) in the letrozole (LET), anastrozole (ANA) or exemestane (EXE) groups compared with the nonendocrine group. For patients who received TAM, compared with the nonendocrine group, TC levels decreased at 1 year, and LDL levels decreased at 1 and 2 years.
TAM may improve LDL and TC levels in premenopausal BC patients. In postmenopausal BC patients, aromatase inhibitors (AIs) may have no adverse effects on lipid profiles, and TAM may have limited beneficial effects on serum lipids.</description><identifier>ISSN: 2234-943X</identifier><identifier>EISSN: 2234-943X</identifier><identifier>DOI: 10.3389/fonc.2021.670897</identifier><identifier>PMID: 35111662</identifier><language>eng</language><publisher>Switzerland: Frontiers Media S.A</publisher><subject>anastrozole ; breast cancer ; endocrine therapy ; letrozol ; lipids ; Oncology ; tamoxifen</subject><ispartof>Frontiers in oncology, 2022-01, Vol.11, p.670897-670897</ispartof><rights>Copyright © 2022 He, Li, Li, Wang, Fan, Li, Fu, Wu, Lv, Luo, Zhong and Chen.</rights><rights>Copyright © 2022 He, Li, Li, Wang, Fan, Li, Fu, Wu, Lv, Luo, Zhong and Chen 2022 He, Li, Li, Wang, Fan, Li, Fu, Wu, Lv, Luo, Zhong and Chen</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c462t-ca926ed18d416d45cd6410f06b5e0dae6488ded46e92c0a4bed70e48f345332d3</citedby><cites>FETCH-LOGICAL-c462t-ca926ed18d416d45cd6410f06b5e0dae6488ded46e92c0a4bed70e48f345332d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801613/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8801613/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35111662$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>He, Tao</creatorcontrib><creatorcontrib>Li, Xu</creatorcontrib><creatorcontrib>Li, Jiayuan</creatorcontrib><creatorcontrib>Wang, Zhu</creatorcontrib><creatorcontrib>Fan, Yuan</creatorcontrib><creatorcontrib>Li, Xiusong</creatorcontrib><creatorcontrib>Fu, Zhoukai</creatorcontrib><creatorcontrib>Wu, Yunhao</creatorcontrib><creatorcontrib>Lv, Qing</creatorcontrib><creatorcontrib>Luo, Ting</creatorcontrib><creatorcontrib>Zhong, Xiaorong</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><title>Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis</title><title>Frontiers in oncology</title><addtitle>Front Oncol</addtitle><description>The aim of this study was to investigate the status of serum lipids during endocrine therapy.
We retrospectively analysed lipid profiles during the 5-year treatment of 1487 consecutive postoperative BC patients. Lipid parameters included triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C). Those biomarkers were measured at baseline and 1, 2, 3, 4 and 5 years following the initiation of endocrine therapy.
For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifen (TAM) group compared with baseline levels (
<0.05), and this decline remained for the following 4 years. Additionally, LDL levels were significantly lower in the TAM group than in the nonendocrine group at all assessment time points (
<0.05). Similarly, TC levels also decreased in the TAM group compared with baseline levels at all assessment time points (
<0.05), and compared with the levels in the nonendocrine group, TC levels were also lower for the first 4 years. For postmenopausal BC patients, there was no significant difference in the lipid profiles (TG, TC, LDL and HDL) in the letrozole (LET), anastrozole (ANA) or exemestane (EXE) groups compared with the nonendocrine group. For patients who received TAM, compared with the nonendocrine group, TC levels decreased at 1 year, and LDL levels decreased at 1 and 2 years.
TAM may improve LDL and TC levels in premenopausal BC patients. In postmenopausal BC patients, aromatase inhibitors (AIs) may have no adverse effects on lipid profiles, and TAM may have limited beneficial effects on serum lipids.</description><subject>anastrozole</subject><subject>breast cancer</subject><subject>endocrine therapy</subject><subject>letrozol</subject><subject>lipids</subject><subject>Oncology</subject><subject>tamoxifen</subject><issn>2234-943X</issn><issn>2234-943X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVks9rFDEUxwdRbKm9e5IcvcyaX5PJeBDqWrWwoEhFPYW3yZvdlNlkTGYKi_-8WbeWNpd8efm-T8LLt6peMroQQndv-hjsglPOFqqlumufVKecC1l3Uvx8-kCfVOc539CyVEMZFc-rE9EwxpTip9WflR-9I8sthA1m8mFOPmzIZXDRFoXkeosJxj3xgbxPCHkiSwgWE_kKk8cw5bcHC_mGeR6mTGJPgDT1L4RUajDUP2IaXJFTinlEO_lbJBcBhn32-UX1rIch4_ndflZ9_3h5vfxcr758ulperGorFZ9qCx1X6Jh2kiknG-uUZLSnat0gdYBKau3QSYUdtxTkGl1LUepeyEYI7sRZdXXkugg3Zkx-B2lvInjzrxDTxkCavB3QdEq2jCplXSMlRwUK12g1atZKCpoW1rsja5zXO3S2jCDB8Aj6-CT4rdnEW6M1ZYqJAnh9B0jx94x5MjufLQ4DBIxzNlzxhqumk7pY6dFqy_Bywv7-GkbNIQLmEAFziIA5RqC0vHr4vPuG_x8u_gJuea5F</recordid><startdate>20220117</startdate><enddate>20220117</enddate><creator>He, Tao</creator><creator>Li, Xu</creator><creator>Li, Jiayuan</creator><creator>Wang, Zhu</creator><creator>Fan, Yuan</creator><creator>Li, Xiusong</creator><creator>Fu, Zhoukai</creator><creator>Wu, Yunhao</creator><creator>Lv, Qing</creator><creator>Luo, Ting</creator><creator>Zhong, Xiaorong</creator><creator>Chen, Jie</creator><general>Frontiers Media S.A</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20220117</creationdate><title>Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis</title><author>He, Tao ; Li, Xu ; Li, Jiayuan ; Wang, Zhu ; Fan, Yuan ; Li, Xiusong ; Fu, Zhoukai ; Wu, Yunhao ; Lv, Qing ; Luo, Ting ; Zhong, Xiaorong ; Chen, Jie</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c462t-ca926ed18d416d45cd6410f06b5e0dae6488ded46e92c0a4bed70e48f345332d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>anastrozole</topic><topic>breast cancer</topic><topic>endocrine therapy</topic><topic>letrozol</topic><topic>lipids</topic><topic>Oncology</topic><topic>tamoxifen</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>He, Tao</creatorcontrib><creatorcontrib>Li, Xu</creatorcontrib><creatorcontrib>Li, Jiayuan</creatorcontrib><creatorcontrib>Wang, Zhu</creatorcontrib><creatorcontrib>Fan, Yuan</creatorcontrib><creatorcontrib>Li, Xiusong</creatorcontrib><creatorcontrib>Fu, Zhoukai</creatorcontrib><creatorcontrib>Wu, Yunhao</creatorcontrib><creatorcontrib>Lv, Qing</creatorcontrib><creatorcontrib>Luo, Ting</creatorcontrib><creatorcontrib>Zhong, Xiaorong</creatorcontrib><creatorcontrib>Chen, Jie</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Frontiers in oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>He, Tao</au><au>Li, Xu</au><au>Li, Jiayuan</au><au>Wang, Zhu</au><au>Fan, Yuan</au><au>Li, Xiusong</au><au>Fu, Zhoukai</au><au>Wu, Yunhao</au><au>Lv, Qing</au><au>Luo, Ting</au><au>Zhong, Xiaorong</au><au>Chen, Jie</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis</atitle><jtitle>Frontiers in oncology</jtitle><addtitle>Front Oncol</addtitle><date>2022-01-17</date><risdate>2022</risdate><volume>11</volume><spage>670897</spage><epage>670897</epage><pages>670897-670897</pages><issn>2234-943X</issn><eissn>2234-943X</eissn><abstract>The aim of this study was to investigate the status of serum lipids during endocrine therapy.
We retrospectively analysed lipid profiles during the 5-year treatment of 1487 consecutive postoperative BC patients. Lipid parameters included triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL-C) and high-density lipoprotein (HDL-C). Those biomarkers were measured at baseline and 1, 2, 3, 4 and 5 years following the initiation of endocrine therapy.
For premenopausal BC patients, LDL levels rapidly decreased at 1 year in the tamoxifen (TAM) group compared with baseline levels (
<0.05), and this decline remained for the following 4 years. Additionally, LDL levels were significantly lower in the TAM group than in the nonendocrine group at all assessment time points (
<0.05). Similarly, TC levels also decreased in the TAM group compared with baseline levels at all assessment time points (
<0.05), and compared with the levels in the nonendocrine group, TC levels were also lower for the first 4 years. For postmenopausal BC patients, there was no significant difference in the lipid profiles (TG, TC, LDL and HDL) in the letrozole (LET), anastrozole (ANA) or exemestane (EXE) groups compared with the nonendocrine group. For patients who received TAM, compared with the nonendocrine group, TC levels decreased at 1 year, and LDL levels decreased at 1 and 2 years.
TAM may improve LDL and TC levels in premenopausal BC patients. In postmenopausal BC patients, aromatase inhibitors (AIs) may have no adverse effects on lipid profiles, and TAM may have limited beneficial effects on serum lipids.</abstract><cop>Switzerland</cop><pub>Frontiers Media S.A</pub><pmid>35111662</pmid><doi>10.3389/fonc.2021.670897</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2234-943X |
| ispartof | Frontiers in oncology, 2022-01, Vol.11, p.670897-670897 |
| issn | 2234-943X 2234-943X |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_96471066cd5442e6a6ebec8e81740a80 |
| source | PubMed Central |
| subjects | anastrozole breast cancer endocrine therapy letrozol lipids Oncology tamoxifen |
| title | Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A15%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lipid%20Changes%20During%20Endocrine%20Therapy%20in%20Breast%20Cancer%20Patients:%20The%20Results%20of%20a%205-Year%20Real-World%20Retrospective%20Analysis&rft.jtitle=Frontiers%20in%20oncology&rft.au=He,%20Tao&rft.date=2022-01-17&rft.volume=11&rft.spage=670897&rft.epage=670897&rft.pages=670897-670897&rft.issn=2234-943X&rft.eissn=2234-943X&rft_id=info:doi/10.3389/fonc.2021.670897&rft_dat=%3Cproquest_doaj_%3E2625265948%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c462t-ca926ed18d416d45cd6410f06b5e0dae6488ded46e92c0a4bed70e48f345332d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2625265948&rft_id=info:pmid/35111662&rfr_iscdi=true |